OTC Athlete’s Foot Drugs Scheduled For FDA Advisory Committee Review
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs advisory committees are scheduled to review OTCs used in treatment of interdigital tinea pedis at a May 6-7 meeting in Rockville, Md
You may also be interested in...
NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
FDA's Nonprescription and Dermatologic & Ophthalmic Drugs advisory committees will discuss clinical trial design and future development programs for drugs treating interdigital Tinea pedis during their May 6-7 meeting in Rockville, MD
NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
FDA's Nonprescription and Dermatologic & Ophthalmic Drugs advisory committees will discuss clinical trial design and future development programs for drugs treating interdigital Tinea pedis during their May 6-7 meeting in Rockville, MD
NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
FDA's Nonprescription and Dermatologic & Ophthalmic Drugs advisory committees will discuss clinical trial design and future development programs for drugs treating interdigital Tinea pedis during their May 6-7 meeting in Rockville, MD